Ocean Pharmaceutical

Ocean Pharmaceutical, established in 2016, is a privately held pharmaceutical company headquartered in Vadodara, Gujarat, India. The company specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations, including tablets, capsules, dry powder injections, lyophilized injections, ointments, and inhalers. Their product portfolio spans various therapeutic areas such as oncology, anti-diabetic, cardiology, pain management, gynecology, anti-infectives, vitamins, minerals, nutrients, gastrointestinal, anti-osteoporosis, anti-malarial, immunosuppressants, anti-bacterial, anti-asthmatics, anti-allergy, contrast media, effervescent tablets, and vaccines.

The company's commitment to quality and customer satisfaction has led to a significant presence in the international market, exporting to over 45 countries. Ocean Pharmaceutical's dedication to providing high-quality products at reasonable prices has positioned it as a leading exporter of various pharmaceutical drugs. (about.me)

Ocean Pharmaceutical operates a WHO–cGMP certified manufacturing facility located in Vadodara, Gujarat, India. This state-of-the-art plant is equipped to produce a wide range of pharmaceutical formulations, including tablets, capsules, dry powder injections, lyophilized injections, ointments, and inhalers. The facility adheres to stringent quality control measures to ensure the safety and efficacy of its products. (about.me)

The leadership team at Ocean Pharmaceutical is headed by Managing Director Mr. Yogesh Parmar, who has been instrumental in steering the company towards its current growth trajectory. Under his guidance, the company has expanded its product portfolio and strengthened its presence in international markets. The team comprises professionals with expertise in various domains, including research and development, manufacturing, quality control, and marketing, contributing to the company's success.

Ocean Pharmaceutical has made significant strides in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to export its pharmaceutical formulations to these regions. This compliance with international standards underscores the company's commitment to quality and safety, facilitating its entry into these competitive markets.

Ocean Pharmaceutical has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has enabled it to access these markets, providing essential medicines to regions with significant healthcare needs. This strategic expansion aligns with the company's mission to make quality healthcare solutions accessible globally.

Ocean Pharmaceutical's geographic strategy demonstrates a balanced approach to market diversification. While the company has a strong presence in regulated markets, it has also strategically penetrated emerging markets, mitigating concentration risk. This diversification allows the company to leverage growth opportunities across different regions, enhancing its global footprint and resilience.

Ocean Pharmaceutical has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has also filed Abbreviated New Drug Applications (ANDAs) for its generic formulations, facilitating market entry in the U.S. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, the company's adherence to international quality standards suggests a commitment to maintaining high manufacturing practices.

Ocean Pharmaceutical's manufacturing facility holds WHO–cGMP certification, indicating compliance with World Health Organization standards for Good Manufacturing Practices. This certification is crucial for exporting pharmaceutical products to various international markets. Additionally, the company's adherence to EU GMP standards further demonstrates its commitment to quality and safety in pharmaceutical manufacturing. (about.me)

In India, Ocean Pharmaceutical operates under the regulatory oversight of the Central Drugs Standard Control Organization (CDSCO). The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with national regulations. Ocean Pharmaceutical also possesses the required export No Objection Certificates (NOCs), facilitating its export operations.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Ocean Pharmaceutical by regulatory authorities. This absence suggests that the company maintains a clean regulatory record, reflecting its commitment to compliance and quality standards.

Ocean Pharmaceutical operates in a competitive landscape, with several companies offering similar pharmaceutical formulations. While specific market share data is not publicly available, the company's focus on high-quality standards and customer-centric approach positions it favorably in the market. Its diverse product portfolio and adherence to international quality standards enable it to compete effectively across various therapeutic segments.

Ocean Pharmaceutical's key differentiators include its commitment to quality, adherence to international manufacturing standards, and a diverse product portfolio covering a wide range of therapeutic areas. The company's focus on affordability without compromising quality makes its products accessible to a broader patient population. Additionally, its strategic expansion into emerging markets demonstrates a proactive approach to global healthcare needs.

Ocean Pharmaceutical's current strategic direction emphasizes the development and export of generic pharmaceutical formulations. The company's adherence to international quality standards and regulatory compliance supports its position in the global market. Looking ahead, Ocean Pharmaceutical aims to expand its product range, strengthen its presence in existing markets, and explore new therapeutic areas, aligning with its mission to provide affordable and high-quality healthcare solutions worldwide.

Ocean Pharmaceutical has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's export volume and consistency reflect its reliability as a supplier. Indicators of reliability include adherence to international quality standards, regulatory compliance, and a customer-centric approach, all contributing to its reputation in the pharmaceutical industry.

Importers should verify the following certifications when considering Ocean Pharmaceutical as a supplier:

• FDA Facility Registration: Confirm the company's registration with the U.S. Food and Drug Administration to ensure compliance with U.S. regulatory standards.

• WHO–cGMP Certification: Verify the manufacturing facility's certification by the World Health Organization for Good Manufacturing Practices, indicating adherence to international quality standards.

• EU GMP Certification: Ensure the company holds certification for Good Manufacturing Practices as per European Union standards, reflecting compliance with European regulatory requirements.

• ISO Certifications: Check for relevant ISO certifications that demonstrate the company's commitment to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from Ocean Pharmaceutical.

When conducting due diligence on Ocean Pharmaceutical, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO–cGMP, EU GMP, and ISO certifications.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities for compliance with international standards.

• Review Product Portfolio: Examine the range of products offered to ensure they meet your requirements.

• Check Export Records: Assess the company's export history and reliability in fulfilling international orders.

• Evaluate Financial Stability: Review financial statements to assess the company's economic health.

• Inspect Quality Control Processes: Ensure robust quality control measures are in place to maintain product standards.

Be cautious of red flags such as expired certifications, unresolved regulatory issues, or inconsistent product quality. Recommended pre-order checks include requesting recent inspection reports, verifying compliance with contractual terms, and assessing the company's responsiveness to inquiries.